Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
09 nov. 2021 16h01 HE
|
Cyclerion Therapeutics, Inc.
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment...
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
22 sept. 2021 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function,...
Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
08 sept. 2021 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
23 août 2021 17h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
29 juil. 2021 17h00 HE
|
Cyclerion Therapeutics, Inc.
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive...
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
22 juil. 2021 16h30 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Announces $18 Million Private Placement
04 juin 2021 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
04 juin 2021 08h00 HE
|
Cyclerion Therapeutics, Inc.
Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties Praliciguat out-licensing further enables...
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
27 mai 2021 16h30 HE
|
Cyclerion Therapeutics, Inc.
Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases...
Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
25 mai 2021 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual...